New Psychoactive Substances (NPS) Reference Materials 2015 Phenethylamines • Amphetamines • Cathinon Es • Try Pt Am I Ne S • P Ip E R a Z I N E S

Total Page:16

File Type:pdf, Size:1020Kb

New Psychoactive Substances (NPS) Reference Materials 2015 Phenethylamines • Amphetamines • Cathinon Es • Try Pt Am I Ne S • P Ip E R a Z I N E S New Psychoactive Substances (NPS) reference materials 2015 phenethylamines • amphetamines • cathinon es • try pt am i ne s • p ip e r a z i n e s • s y n t h e t i c c a n n a b i n o i d s • d i s s o c i a t i v e s • d e s i g n e r b e n z o d i a z e p i n e s • a r y l c y c l o h e x a m i n e s LGC Quality - ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 reference materials Solutions and powders for all your analytical needs: • Drugs of abuse • Therapeutic drug monitoring • Derivatizing reagents • Steroids • Ethanol • Stable isotope labeled • Metabolites compounds • New psychoactive • Custom synthesis substances (NPS) and many more • Prescription drugs www.lgcstandards.com • Science for a safer world LGC Quality - ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 © LGC Limited, 2014. All rights reserved. LGC Standards is part of the LGC Group. LoGiCal is a registered trademark of LGC Standards GmbH 4063/CB/0714 4063_LoGiCal_advert_A4_v3.indd 1 8/12/2014 11:35:36 AM Welcome to our latest catalogue of reference standards for New Psychoactive Substances (NPS) We have expanded the format slightly to include sequential reference numbers for the many materials listed in the various sections. These reference numbers will help you to easily identify and order the reference materials you need. This listing can be divided into three broad groups. Sections 1-7 are compounds that are generally considered to be stimulants and hallucinogens and are comprised of phenethylamines, tryptamines, cathinones, piperazines, and amphetamines. Sections 8-9 list the synthetic cannabinoids and their metabolites. Sections 10-11 detail other NPS chemicals, including designer variants of pharmaceuticals such as benzodiazepines and opioids, plant chemicals, and the dissociative drugs. At the beginning of each Section, a generic chemical structure has been given to aid with identification of the numerous NPS that are available. In addition, there is an explanation of the trivial nomenclature used with the synthetic cannabinoids at the beginning of Section 8. Many of these products are produced under the rigorous quality assurance standards set out in ISO Guide 34. If you don’t see what you are looking for, please contact your local sales office as the range of these products is continuously evolving. We look forward to hearing from you. The LGC Team Contents 1. Phenethylamines 8. Synthetic cannabinoids 1.1 Simple phenethylamines ............................................. 5 Organisation of our listing of available reference standards ... 20 1.2. “2C-X” compounds ..................................................... 5 (1) Pyrrole core (2,5-Dimethoxyphenethylamines) 8.1 Naphthoyl pyrroles .............................................. 22 1.3 “2C-X-NBOMe” and related derivatives ...................... 6 (2) Indene core 1.4 Methylenedioxyphenethylamines ................................ 6 8.2 Naphthyl indenes ................................................ 22 1.5 Trialkoxyphenethylamines ........................................... 7 (3) Indole core 1.6 “Fly” and “Dragonfly” compounds ................................ 7 8.3 Naphthoyl indoles ............................................... 22 1.7 “Benzofuries” (APBs and APDBs) ............................... 7 8.4 Naphthyl methyl indoles ..................................... 24 1.8 Other phenethylamine-related compounds ................. 8 8.5 Phenylacetyl indoles ........................................... 25 8.6 Benzoyl indoles ................................................... 25 2. Metabolites of ‘ecstasy’ chems ......................................... 8 8.7 Pyridinoyl indoles ................................................ 25 3. Amphetamines 8.8 Adamantoyl indoles ............................................ 26 3.1 Amphetamines ................................................................ 9 8.9 Tetramethylcyclopropoyl indoles ........................ 26 3.2 Dimethoxyamphetamines ............................................... 9 8.10 3,4,4-Trimethyl-pent-2-en-1-one indoles .......... 26 3.3 Trialkoxyamphetamines ............................................... 10 8.11 Indole carboxamides ......................................... 26 3.4 N-Methyl amphetamines ............................................. 10 8.12 Indole carboxylates ........................................... 27 3.5 N-Ethyl amphetamines ................................................. 11 8.13 Quinolinyl indole carboxylates .......................... 27 3.6 Other amphetamines .................................................... 11 8.14 Pyridinoyl indoles .............................................. 28 8.15 Piperidinyl indole carboxamides ....................... 28 4. Cathinones 8.16 Thiazole indoles ................................................ 28 4.1 Beta-keto “2C-X” compounds .................................... 11 (4) Indazole core 4.2 Simple cathinones ..................................................... 11 8.17 Naphthoyl indazoles ......................................... 29 4.3 N-Methyl cathinone and derivatives ......................... 12 8.18 Tetramethylcyclopropoyl indazoles ................... 29 4.4 N-Ethyl cathinone and derivatives ............................ 12 8.19 Indazole carboxamides .................................... 29 4.5 Simple butanones ..................................................... 13 8.27 Indazole carboxylates ....................................... 30 4.6 Simple pentanones ................................................... 13 8.20 Naphthyl indazole carboxylates ........................ 30 4.7 Simple hexanones .................................................... 13 8.21 Quinolinyl indazole carboxamides .................... 30 4.8 Other simple cathinones ........................................... 14 8.22 Quinolinyl indazole carboxylates ...................... 30 4.9 Methylenedioxycathinones (C3 to C5 sidechains) ... 14 (5) Benzimidazole core 4.10 Ethylenedioxycathinones .......................................... 15 8.23 Naphthoyl benzimidazoles ............................... 30 4.11 Pyrrolidinocathinones (C3 to C9 sidechains) ........... 15 (6) Carbazole core 4.12 Methylenedioxypyrrolidinocathinones ...................... 15 8.24 Naphthoyl carbazoles ....................................... 31 (C3 to C6 side chain) (7) Azaindole core 4.13 Naphthyl cathinones and pyrrolidinocathinones ...... 16 8.28 Azaindole carboxamides .................................. 31 4.14 Related materials ...................................................... 16 (8) Other synthetic cannabinoids ....................................... 31 5. Metabolites of Cathinones .............................................. 16 8.25 Single components ........................................... 31 8.26 Mixed standards ............................................... 31 6. Tryptamines 6.1 Tryptamine ................................................................ 17 9. Synthetic cannabinoid metabolites ............................... 32 6.2 Alpha-Alkyl tryptamines ............................................ 17 10. Other NPS chemicals 6.3 N-Alkyl tryptamines .................................................... 17 10.1 Cocaine-like materials .............................................. 36 6.4 Ring-Methoxy N-Alkyl tryptamines ........................... 18 10.2 Benzodiazepine-like materials .................................. 37 6.5 Ring-Hydroxy N-Alkyl tryptamines ............................ 18 10.3 Other pharmaceuticals ............................................. 37 6.6 Ring-Acetoxy N-Alkyl tryptamines ............................ 18 10.4 ‘Designer’ forms of pharmaceuticals ......................... 37 6.7 Other mushroom hallucinogens ............................... 18 10.5 Pipradrol-related materials ....................................... 37 6.8 Related compounds .................................................. 19 10.6 Plant chemicals ......................................................... 38 7. Piperazines 10.7 Materials with alcohol-like effects ............................. 38 7.1 Benzylpiperazines ..................................................... 19 10.8 Indanes ..................................................................... 38 7.2 Phenylpiperazines .................................................... 19 10.9 Synthetic opioids ....................................................... 38 10.10 Dissociatives ............................................................ 38 10.11 Thiophene analogues of amphetamines ................. 38 10.12 Other materials ....................................................... 39 11. Aryl Cyclohexylamines .................................................. 40 Ref. no. Substance Other names 1. Phenethylamines 1.1 Simple phenethylamines 2 β 3 NH2 α 4 6 5 1.1.1 PEA 2-Phenethylamine 1.1.2 N-Me-PEA N-Methyl-2-phenylethylamine 1.1.3 α,α-Dimethyl-PEA Phentermine 1.1.4 α,α-Dimethyl-PEA-D5 1.1.5 β-Methyl-PEA 2-Phenylpropan-1-amine 1.1.6 N,β-Dimethyl-PEA Phenylpropylmethylamine 1.1.7 N,N-Diethyl-PEA 1.1.8 β-Methoxy-PEA 2-MeO-2-phenylethylamine 1.1.9 α-Ethyl-PEA 2-Amino-1-phenylbutane 1.1.10 N-Methyl-α-ethyl-PEA 2-Methylamino-1-phenylbutane 1.1.11 N-Ethyl-α-ethyl-PEA 2-Ethylamino-1-phenylbutane 1.1.12 4-Chloro-α-ethyl-PEA 4-CAB 1.2. “2C-X” compounds (2,5-Dimethoxyphenethylamines) O R 2 NH2 3 6 4 R'/X 5 O 1.2.1 2C-B ('Nexus') 2,5-DiMeO-4-Br-PEA 1.2.2 2C-B-D6 1.2.3 2C-C 2,5-DiMeO-4-Cl-PEA 1.2.4 2C-C-D6 1.2.5 2C-D 2,5-DiMeO-4-Me-PEA 1.2.6 2C-D-D6 1.2.7
Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
    [Show full text]
  • The 2006 Prohibited List International Standard
    The World Anti-Doping Code THE 2006 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2006. THE 2006 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2006 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α- methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α- dimethyl-5α-androstane-3-one-17β-ol); methyldienolone
    [Show full text]
  • Drug Abuse in Iowa Evolving Issues & Emerging Trends
    1 Drug Abuse in Iowa Evolving Issues & Emerging Trends Iowa Office of Drug Control Policy September 2016 2 Rapid Changes + Mixed Messages = ???s Evolving Risks involving Medicines, Synthetics, Marijuana, etc. • What’s new (what is it, what’s in it, what’s it’s effect)? • Does it heal or hurt (medicine or menace)? • Is it legal or illegal? • What do we tell children (or anyone else) about it? • How is it different now, compared to what I experienced? • What do we know about it & when will we know more? • What’s next? 3 Youth Substance Use 40-Year Trends Current Use (past 30 days) Among U.S. 12th Graders 80% 70% 60% 50% 40% Alcohol 30% Marijuana 20% 10% Cigarettes 0% Monitoring the Future, 1975-2015 4 Drugs of Choice: All Iowans Primary Substance of Choice by Iowans in Treatment 90% 80% 70% 60% Alcohol 50% 50% Marijuana 40% Meth Cocaine 30% 25.6% Heroin Other 20% 14.8% 10% 6.3% 1.7% 0% 1.6% IDPH, 2014 5 Iowa Youth Substance Abuse 6th, 8th and 11th Grade Users, Last 30-Days 25% 23% 20% Alcohol 15% 14% Tobacco 12% Other Drug 9% 10% 10% Rx OTC 6% Meth 5% 4% 4% 3% 3% 1% 0% 1% 2002 2005 2008 2010 2012 2014 Iowa Youth Survey, 2014 6 Iowa Drug-Related Traffic Fatalities Number Killed in 2014 Testing Positive for Illicit Drugs 16 15% of those killed in Iowa traffic fatalities 14 in 2014 tested positive for illicit drugs. 12 10 8 6 4 2 0 Marijuana Meth Rx Synthetic Opium Other Does not include alcohol-related fatalities.
    [Show full text]
  • Pharmacokinetics of Mephedrone Enantiomers in Whole Blood After a Controlled Intranasal Administration to Healthy Human Volunteers
    pharmaceuticals Article Pharmacokinetics of Mephedrone Enantiomers in Whole Blood after a Controlled Intranasal Administration to Healthy Human Volunteers Joanna Czerwinska 1, Mark C. Parkin 1,2, Agostino Cilibrizzi 3 , Claire George 4, Andrew T. Kicman 1, Paul I. Dargan 5,6 and Vincenzo Abbate 1,* 1 King’s Forensics, Department of Analytical, Environmental and Forensic Sciences, King’s College London, London SE1 9NH, UK; [email protected] (J.C.); MarkParkin@eurofins.co.uk (M.C.P.); [email protected] (A.T.K.) 2 Toxicology Department, Eurofins Forensic Services, Teddington TW11 0LY, UK 3 Institute of Pharmaceutical Science, King’s College London, London SE1 9NH, UK; [email protected] 4 Alere Toxicology (Now Part of Abbott), Abingdon OX14 1DY, UK; [email protected] 5 Clinical Toxicology, Faculty of Life Sciences and Medicine, King’s College London, London SE1 9NH, UK; [email protected] 6 Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s Health Partners, London SE1 7EH, UK * Correspondence: [email protected] Abstract: Mephedrone, which is one of the most popular synthetic cathinones, has one chiral centre and thus exists as two enantiomers: R-(+)-mephedrone and S-(−)-mephedrone. There are some preliminary data suggesting that the enantiomers of mephedrone may display enantioselective phar- macokinetics and exhibit different neurological effects. In this study, enantiomers of mephedrone were resolved via chromatographic chiral recognition and the absolute configuration was unambigu- ously determined by a combination of elution order and chiroptical analysis (i.e., circular dichroism). A chiral liquid chromatography tandem mass spectrometry method was fully validated and was Citation: Czerwinska, J.; Parkin, M.C.; applied to the analysis of whole blood samples collected from a controlled intranasal administra- Cilibrizzi, A.; George, C.; Kicman, A.T.; tion of racemic mephedrone hydrochloride to healthy male volunteers.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Programme & Abstracts
    The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday.
    [Show full text]
  • Cross Reaction Guide
    Individual Reaction Key Methadone(MTD) Phencyclidine(PCP) Amphetamines(AMP) Tricyclic Antidepressants(TCA) Oxycodone(OXY) Barbiturates(BAR) Methamphetamines(MET) Benzodiazepines(BZO) Tramadol(TML) Opiates(OPI, MOP, MOR) Marijuana(THC) Ecstasy(MDMA) Cotinine(COT) Cocaine(COC) Buprenorphine(BUP) Propoxyphene(PPX) Non-reactive Multiple Reaction Key MET and AMP OPI and OXY MDMA and MET MDMA and AMP MET and TCA Generic Name of Compound Trade Name of Compound Results 6-Acetylmorphine N/A Positive: Opiates(OPI, MOP, MOR) Aceta, Acephen, Apacet, Dapacen, Feverall, Acetaminophen (aka Paracetamol) Tylenol, Excedrin (combination), Panadol, Non-reactive Tempra Acetaminophen with Codeine (aka Positive: Opiates(OPI, MOP, MOR) Tylenol 3, Tylenol with Codeine Paracetamol with Codeine) Potential reactants: Dihydrocodeine Acetophenetidin Phenacetin Non-reactive Aspirin, Anadin, Anasin, Bufferin, Caprin, Acetylsalicyclic Acid Disprin, Ecotrin, Empirin, Excedrin Non-reactive (combination) Allobarbital N/A Positive: Barbiturates(BAR) Alphenol N/A Positive: Barbiturates(BAR) Positive: Benzodiazepines(BZO) Potential Alprazolam Xanax reactants: Oxaprozin (Daypro), Sertraline Aluminum Chloride Hexahydrate Drichlor, Anhydrol Forte Non-reactive Alu-Cap, Alisone, Gastrocote, Kolanticon, Aluminum Hydroxide Non-reactive Maalox TC, Mucogel, Pyrogastrone, Topal Alverine Citrate Spasmonal, Spasmonal Fibre Non-reactive Amantadine Symmetrel Positive: Amphetamines(AMP) SpearesMedical.comAminopyrine N/A Non-reactive Elavil, Lentizol, Tryptizol, Triptafen, Triptafen- Amitriptyline
    [Show full text]
  • References to Argentina
    References to Argentina Part 1 RECENT STATISTICS AND TREND ANALYSIS OF ILLICIT DRUG MARKETS A. EXTENT OF ILLICIT DRUG USE AND HEALTH CONSEQUENCES The Americas (pages 12 to 14 WDR 13) In the Americas, a high prevalence of most illicit drugs, essentially driven by estimates in North America, was observed, with the prevalence of cannabis (7.9 per cent) and cocaine (1.3 per cent) being particularly high in the region. South America, Central America and the Caribbean The annual prevalence of cocaine use in South America (1.3 per cent of the adult population) is comparable to levels in North America, while it remains much higher than the global average in Central America (0.6 per cent) and the Caribbean (0.7 per cent). Cocaine use has increased significantly in Brazil, Costa Rica and, to lesser extent, Peru while no change in its use was reported in Argentina. The use of cannabis in South America is higher (5.7 per cent) than the global average, but lower in Central America and Caribbean (2.6 and 2.8 per cent respectively). In South America and Central America the use of opioids (0.3 and 0.2 per cent, respectively) and Ecstasy (0.1 per cent each) also remain well below the global average. While opiates use remains low, countries such as Colombia report that heroin use is becoming increasingly common among certain age groups and socio-economic classes.30 Part 2 NEW PSYCHOACTIVE SUBSTANCES C. THE RECENT EMERGENCE AND SPREAD OF NEW PSYCHOACTIVE SUBSTANCES (page 67 WDR 13) Spread at the global level Number of countries reporting the emergence of new psychoactive substances Pursuant to Commission on Narcotic Drugs resolution 55/1, entitled “Promoting international cooperation in responding to the challenges posed by new psychoactive substances”, in 2012 UNODC sent a questionnaire on NPS to all Member States, to which 80 countries and territories replied.
    [Show full text]
  • The Enantioselective-Controlled Delivery of Propranolol by Cellulose
    The Enantioselective-Controlled Delivery of Propranolol by Cellulose Membrane Grafted with Molecularly Imprinted Polymer Chatchada Bodhibukkana A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy in Pharmaceutical Sciences Prince of Songkla University 2008 i Copyright of Prince of Songkla University Thesis Title The Enantioselective-Controlled Delivery of Propranolol by Cellulose Membrane Grafted with Molecularly Imprinted Polymer Author Miss Chatchada Bodhibukkana Major program Pharmaceutical Sciences Major Advisor Examining Committee ………………………………………… ………………………………Chairperson (Assoc. Prof. Dr. Roongnapa Srichana) (Assoc. Prof. Dr. Ruedeekorn Wiwattanapatapee) ………………………………Committee Co-advisor (Assoc. Prof. Dr. Varaporn Junyaprasert ) ………………………………………… ………………………………Committee (Assoc. Prof. Dr. Teerapol Srichana) (Assoc. Prof. Dr. Roongnapa Srichana) ………………………………………… ………………………………Committee (Prof. Gary P. Martin) (Assoc. Prof. Dr. Teerapol Srichana) The Graduate School, Prince of Songkla University, has approved this thesis as partial fulfillment of the requirements for the Doctor of Philosophy Degree in Pharmaceutical Sciences …………………………………………… (Assoc. Prof. Dr. Krerkchai Thongnoo) Dean of Graduate School ii propranolol !" #$ %& '(")* %&% **+, - )!,!. */*- 0 1,!2 ( 2550 ! 26 7 %8%),(9-+:%&;*,< + (composite membrane) #$ ; :%%* %&% **+, (Molecularly imprinted polymer, MIP) *& !" L* %&L* ; ; S-enantiomer ; racemic propranolol + ,: N68 +%& +N$'O !,& %&$*- #$ ")
    [Show full text]
  • Sensory and Signaling Mechanisms of Bradykinin, Eicosanoids, Platelet-Activating Factor, and Nitric Oxide in Peripheral Nociceptors
    Physiol Rev 92: 1699–1775, 2012 doi:10.1152/physrev.00048.2010 SENSORY AND SIGNALING MECHANISMS OF BRADYKININ, EICOSANOIDS, PLATELET-ACTIVATING FACTOR, AND NITRIC OXIDE IN PERIPHERAL NOCICEPTORS Gábor Peth˝o and Peter W. Reeh Pharmacodynamics Unit, Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Pécs, Pécs, Hungary; and Institute of Physiology and Pathophysiology, University of Erlangen/Nürnberg, Erlangen, Germany Peth˝o G, Reeh PW. Sensory and Signaling Mechanisms of Bradykinin, Eicosanoids, Platelet-Activating Factor, and Nitric Oxide in Peripheral Nociceptors. Physiol Rev 92: 1699–1775, 2012; doi:10.1152/physrev.00048.2010.—Peripheral mediators can contribute to the development and maintenance of inflammatory and neuropathic pain and its concomitants (hyperalgesia and allodynia) via two mechanisms. Activation Lor excitation by these substances of nociceptive nerve endings or fibers implicates generation of action potentials which then travel to the central nervous system and may induce pain sensation. Sensitization of nociceptors refers to their increased responsiveness to either thermal, mechani- cal, or chemical stimuli that may be translated to corresponding hyperalgesias. This review aims to give an account of the excitatory and sensitizing actions of inflammatory mediators including bradykinin, prostaglandins, thromboxanes, leukotrienes, platelet-activating factor, and nitric oxide on nociceptive primary afferent neurons. Manifestations, receptor molecules, and intracellular signaling mechanisms
    [Show full text]
  • General Drug and Explosive Detection
    Ζ'HQWDȇV'UXJ'HWHFWLRQDQGΖGHQWLILFDWLRQWHVWNLWVRIIHUEUHDNWKURXJKLQQRYDWLRQVORQJ DZDLWHGE\WKHIRUHQVLFPDUNHW8QWLOUHFHQWO\RQO\GLIILFXOWWRXVHDQGKDUGWRXQGHUVWDQG WHVWNLWVZLWKPDQ\FRQVWUDLQWVDQGOLPLWDWLRQVZHUHDYDLODEOHΖ'HQWDȇVNLWVPDNHWKH WDVNVIDFHGE\SDUHQWVHGXFDWRUVHPSOR\HUVDQGODZHQIRUFHPHQWRIILFHUVHDVLHU IDVWHUIDUVDIHUDQGPRUHFRVWHIIHFWLYHWKDQDQ\VLPLODUNLWDYDLODEOH .H\%HQHILWV .H\0DUNHWV ႑(DV\IDVWDQGVLPSOHWRXVH1RRWKHUWHVWVDUH ႑/DZHQIRUFHPHQW DVVWUDLJKWIRUZDUG ႑0LOLWDU\ ႑$FFXUDWHDQGUHOLDEOHDWH[WUHPHWHPSHUDWXUHV ႑&XVWRPV ႑&OHDUUHVXOWVLQVHFRQGV ႑6HFXULW\DJHQFLHV ႑/RQJVKHOIOLIH XSWR\HDUV ZLWKQRVWRUDJH ႑*RYHUQPHQWDJHQFLHV UHVWULFWLRQV ,'7 '($)%Ζ&Ζ$ ,'7 ,'7 ႑6DIH$FWXDOO\YHU\VDIH1RFRQWDFWZLWK *HQHUDO6FUHHQLQJ ႑3ULVRQV FKHPLFDOVRUVXEVWDQFHV1RLQKDODWLRQRI .HWDPLQH /LTXLG *+% 'UXJV &RUSRUDWH+5GHSDUWPHQWV YDSRUVQRSURWHFWLYHJHDUQHHGHG ႑ ΖGHQWLILFDWLRQ ΖGHQWLILFDWLRQ ΖGHQWLILFDWLRQ ႑6DIHWRGLVSRVH6HOIFRQWDLQHGQHXWUDOL]DWLRQ ႑3ULYDWHUHVLGHQFHV )LHOG7HVW.LW ႑6PDOODQGYHU\UXJJHG ႑6FKRROV8QLYHUVLWLHV )LHOG7HVW.LW )LHOG7HVW.LW ႑&DQEHXVHGDQ\ZKHUHDQ\WLPH ႑5HKDELOLWDWLRQIDFLOLWLHV ႑7KHFRORUWHVWLVEDVHGRQWKHVDPHFKHPLVWU\DV ႑ƀ+\GUR[\EXW\ULFDFLG *+% LVDFHQWUDO ႑7KHWHVWGHWHFWVGUXJVLQFOXGLQJFRFDLQH ႑$YDLODEOHZLWKYDULRXVSUREHV ႑%RUGHUFRQWURO IRUWKHVROLGWHVW QHUYRXVV\VWHPGHSUHVVDQWXVHGDVDQ KHURLQDPSKHWDPLQHHFVWDV\DVZHOODVQHZ 7RXFK6ZLSH6QLIIHURU6DPSOHU LQWR[LFDQW GHVLJQHUGUXJV ႑(PHUJHQF\URRPV ႑7KHNLWFRQWDLQVDQRYHOVDPSOHUIRUWKHHDV\ ႑2XUNLWV'2WHVWOLTXLGV WHVWLQJRIOLTXLGV ႑&RPPRQVWUHHWQDPHVLQFOXGH*/LTXLG ႑7KHWHVWLVEDVHGRQDQRYHOFRORUWHVWIRU */LTXLG;/LTXLG(*HRUJLD+RPH%R\ DONDORLGV
    [Show full text]
  • Positive Allosteric Modulators (Pams) in Mouse Models of Overt Cannabimimetic Activity, Subjective Drug Effects, and Neuropathic Pain
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2021 Investigating Cannabinoid Type-1 Receptor (CB1R) Positive Allosteric Modulators (PAMs) in Mouse Models of Overt Cannabimimetic Activity, Subjective Drug Effects, and Neuropathic Pain Jayden Elmer Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Behavioral Neurobiology Commons, Behavior and Behavior Mechanisms Commons, Medicinal and Pharmaceutical Chemistry Commons, Nervous System Diseases Commons, and the Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/6777 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. 2021 Investigating Cannabinoid Type-1 Receptor (CB1R) Positive Allosteric Modulators (PAMs) in Mouse Models of Overt Cannabimimetic Activity, Subjective Drug Effects and Neuropathic Pain Jayden A. Elmer Investigating Cannabinoid Type-1 Receptor (CB1R) Positive Allosteric Modulators (PAMs) in Mouse Models of Overt Cannabimimetic Activity, Subjective Drug Effects and Neuropathic Pain A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University By Jayden Aric Elmer Bachelor of Science, University of Virginia, 2018 Director: Dr. Aron Lichtman, Professor, Department of Pharmacology & Toxicology; Associate Dean of Research and Graduate Studies, School of Pharmacy Virginia Commonwealth University Richmond, Virginia July 2021 Acknowledgements I would first like to extend my gratitude towards the CERT program at VCU. The CERT program opened the doors for me to get involved in graduate research.
    [Show full text]